Drug Information

Drug General Information
Drug ID
D05YQT
Former ID
DIB005030
Drug Name
LBR-101
Drug Type
Antibody
Indication Migraine [ICD9: 346; ICD10:G43] Phase 1 [532603]
Company
Labrys biologics
Target and Pathway
Target(s) Calcitoningene-related peptide type 1 receptor Target Info [532603]
KEGG Pathway Neuroactive ligand-receptor interaction
Vascular smooth muscle contraction
Reactome G alpha (s) signalling events
Calcitonin-like ligand receptors
WikiPathways GPCRs, Class B Secretin-like
Endothelin Pathways
GPCR ligand binding
GPCR downstream signaling
References
Ref 532603Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013 Dec 23;34(7):483-492.
Ref 532603Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013 Dec 23;34(7):483-492.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.